Robert Delage

Pelland AA, Deschênes-Simard X, Savard X, Giguère P, Spillane D, Barabé F, Laroche V, Munger M, Gallagher G, Marcoux N, Cantin G, Chénard-Poirier M, Delage R, Lalancette M, Veilleux O, Assouline SE, Lemieux C

Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study

Leuk Lymphoma, 2024.

Résumé | Liens:

Teichman J, Geddes M, Zhu N, Keating MM, Sabloff M, Christou G, Leber B, Khalaf D, St-Hilaire E, Finn N, Shamy A, Yee KWL, Storring JM, Nevill TJ, Delage R, Elemary M, Banerji V, Houston B, Mozessohn L, Chodirker L, Zhang L, Siddiqui M, Parmentier A, Leitch HA, Buckstein RJ

High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes

Haematologica, 108 (2), 2023.

Résumé | Liens:

Benoit A, B Boies MH, Déry N, M Garcia L, Simard M, Poirier M, Delage R, Lortal Canguilhem B, Doyle C, Larouche JF, Couture F, Lemieux C

CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study

Clin Lymphoma Myeloma Leuk, 23 (3), 2023.

Résumé | Liens:

Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R,

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Lancet, 401 (10373), 2023.

Résumé | Liens:

Perusini MA, Novitzky-Basso I, Atenafu EG, Forrest D, Bence-Bruckler I, Savoie L, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Laneuville P, Paulson K, Stockley T, Lipton JH, Leber B, Kim DDH

Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study

Br J Haematol, 203 (5), 2023.

Résumé | Liens:

Kim DDH, Kim TS, Atenafu EG, Novitzky Basso I, Forrest D, Bence-Bruckler I, Savoie L, Busque L, Keating MM, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B

BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase

Br J Haematol, 196 (1), 2022.

Résumé | Liens:

Buckstein R, Chodirker L, Mozessohn L, Yee KWL, Geddes M, Zhu N, Shamy A, Leitch HA, Christou G, Banerji V, Brian L, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Delage R, Parmentier A, Thambipillai A, Siddiqui M, Westcott C, Cameron C, Mamedov A, Spin P, Tang D

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry

Leuk Lymphoma, 63 (13), 2022.

Résumé | Liens:

Kim DDH, Novitzky-Basso I, Kim TS, Atenafu EG, Forrest D, Savoie L, Bence-Bruckler I, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Paulson K, Stockley T, Laneuville P, Lipton JH, Kamel-Reid S, Leber B

Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial

Br J Haematol, 193 (4), 2021.

Résumé | Liens:

Amitai I, Geddes M, Zhu N, Keating MM, Sabloff M, Christou G, Leber B, Khalaf D, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Chodirker L, Mozessohn L, Parmentier A, Siddiqui M, Mamedov A, Zhang L, Buckstein R

Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study

Br J Haematol, 194 (2), 2021.

Résumé | Liens:

Simpson-Poirier K, Harnois M, Olney HJ, Sirhan S, Gratton MO, Assouline S, Laneuville P, Delage R, Mollica L, Busque L, Szuber N

Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group

Am J Hematol, 96 (6), 2021.

| Liens: